Comparative Pharmacology
Head-to-head clinical analysis: DESMOPRESSIN ACETATE versus NOCDURNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMOPRESSIN ACETATE versus NOCDURNA.
DESMOPRESSIN ACETATE vs NOCDURNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin acetate is a synthetic analog of antidiuretic hormone (ADH) that binds to V2 receptors in the renal collecting ducts, increasing water reabsorption and reducing urine output. It also stimulates release of von Willebrand factor and factor VIII from endothelial cells via V2 receptor activation.
NOCDURNA (desmopressin) is a synthetic analog of vasopressin, an antidiuretic hormone. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine production.
IV/SC: 0.3-0.4 mcg/kg IV/SC once; may repeat once after 24 hours. Intranasal: 100-400 mcg (0.1-0.4 mL) once; may repeat once after 24 hours. Oral: 300-600 mcg three times daily.
50 mcg sublingual tablet once daily, 1 hour before bedtime.
None Documented
None Documented
Terminal half-life 2-4 hours; prolonged in renal impairment (up to 9 hours)
~2.8 hours; short half-life suitable for nocturnal dosing with minimal morning carryover
Renal (60-70% unchanged), minimal biliary/fecal (<10%)
Renal: >80% as unchanged drug; fecal: ~10%
Category A/B
Category C
Vasopressin Analog
Vasopressin Analog